Contineum Therapeutics (CTNM) Competitors $3.86 +0.03 (+0.78%) Closing price 04:00 PM EasternExtended Trading$4.11 +0.25 (+6.45%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. ERAS, KMDA, VERV, TECX, ORIC, RAPP, RVNC, ORGO, TKNO, and MBXShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Erasca (ERAS), Kamada (KMDA), Verve Therapeutics (VERV), Tectonic Therapeutic (TECX), ORIC Pharmaceuticals (ORIC), Rapport Therapeutics (RAPP), Revance Therapeutics (RVNC), Organogenesis (ORGO), Alpha Teknova (TKNO), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Erasca Kamada Verve Therapeutics Tectonic Therapeutic ORIC Pharmaceuticals Rapport Therapeutics Revance Therapeutics Organogenesis Alpha Teknova MBX Biosciences Contineum Therapeutics (NASDAQ:CTNM) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations. Does the MarketBeat Community favor CTNM or ERAS? Erasca received 17 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 73.17% of users gave Erasca an outperform vote. CompanyUnderperformOutperformContineum TherapeuticsOutperform Votes13100.00% Underperform VotesNo VotesErascaOutperform Votes3073.17% Underperform Votes1126.83% Is CTNM or ERAS more profitable? Erasca's return on equity of -42.26% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -49.92% -20.52% Erasca N/A -42.26%-34.97% Which has higher valuation and earnings, CTNM or ERAS? Contineum Therapeutics has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M2.00$22.72M-$1.97-1.96ErascaN/AN/A-$125.04M-$0.62-1.97 Does the media prefer CTNM or ERAS? In the previous week, Erasca had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 8 mentions for Erasca and 7 mentions for Contineum Therapeutics. Erasca's average media sentiment score of 1.00 beat Contineum Therapeutics' score of -0.30 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in CTNM or ERAS? 67.8% of Erasca shares are held by institutional investors. 11.3% of Contineum Therapeutics shares are held by insiders. Comparatively, 14.4% of Erasca shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate CTNM or ERAS? Contineum Therapeutics currently has a consensus target price of $22.50, suggesting a potential upside of 482.90%. Erasca has a consensus target price of $4.57, suggesting a potential upside of 274.71%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Contineum Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Erasca 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryErasca beats Contineum Therapeutics on 9 of the 16 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.87M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-1.968.9226.8419.71Price / Sales2.00253.80392.34117.39Price / Cash6.3565.8538.2534.62Price / Book-1.046.466.794.50Net Income$22.72M$143.98M$3.23B$248.18M7 Day Performance0.52%3.04%4.07%1.14%1 Month Performance-22.02%7.44%12.52%15.20%1 Year Performance-75.88%-2.46%16.83%6.56% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics2.2039 of 5 stars$3.86+0.8%$22.50+482.9%-75.6%$99.87M$50M-1.9631Earnings ReportAnalyst ForecastERASErasca3.608 of 5 stars$1.39flat$4.83+247.7%-42.9%$393.77MN/A-1.67120Gap UpKMDAKamada3.9388 of 5 stars$6.82-0.9%$14.67+115.1%+26.8%$392.01M$160.95M24.36360Earnings ReportAnalyst UpgradeAnalyst RevisionVERVVerve Therapeutics3.5256 of 5 stars$4.35+2.8%$25.75+492.0%-22.5%$387.77M$32.33M-1.77110Trending NewsEarnings ReportAnalyst RevisionGap UpTECXTectonic Therapeutic3.6136 of 5 stars$20.71+4.8%$72.40+249.6%N/A$386.68MN/A-3.52120Positive NewsGap UpORICORIC Pharmaceuticals4.4546 of 5 stars$5.41+6.5%$19.17+254.3%-37.6%$384.59MN/A-2.9780Positive NewsRAPPRapport Therapeutics1.5382 of 5 stars$10.47+2.1%$32.67+212.0%N/A$382.13MN/A-3.03N/AGap UpRVNCRevance Therapeutics1.901 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500Analyst ForecastORGOOrganogenesis4.019 of 5 stars$2.98-2.6%$5.50+84.6%+17.7%$378.03M$482.04M-49.67950News CoverageTKNOAlpha Teknova1.7334 of 5 stars$7.06+1.4%$8.50+20.4%+275.4%$377.29M$37.75M-9.54240Gap UpMBXMBX Biosciences2.9494 of 5 stars$11.14+0.3%$37.50+236.6%N/A$371.34MN/A0.0036News CoveragePositive News Related Companies and Tools Related Companies ERAS Competitors KMDA Competitors VERV Competitors TECX Competitors ORIC Competitors RAPP Competitors RVNC Competitors ORGO Competitors TKNO Competitors MBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTNM Stock Free CTNM Stock Alerts